Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

CBCue Biopharma, Inc.

35 indications, side-by-side phase, drug & LoA

$24.53

-2.56 (-9.45%)

D 26Pipeline Score Richly Valued Biotech · Clinical
Market Cap
86.86 M
EPS
-5.52
P/E Ratio
-
Value Trade
1.83 M
SEC Financials
Q1 2026

  • Dilution Risk

    80%

  • Revenue

    5.69 M

  • R&D Expenses

    6.90 M

  • Operating CF

    -10.94 M

  • Total Assets

    30.88 M

  • Total Liabilities

    9.27 M

  • Equity

    21.61 M

  • D/E Ratio

    12,345

-7.89 %
Week
41.7 %
1 Month
144.25 %
3 Month
32.53 %
6 Month
-95 %
5 Year
-94.03 %
All Time
Cash Data
Distressed

  • Cash Position

    16.38 M

  • Monthly Burn

    3.65 M

  • Runway

    3.6 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 14, 2026
Overview
Volume
86.60 K
52 Week Range
4.97 - 41.42
% held by Insiders
8.55 %
% held by Institutions
16.98 %
Enterprise Value
73.92 M
Total Shares
97.44 M
Short %
0.29 %
Float Shares
94.71 M
Company Description
HQ: 40 GUEST STREET, BOSTON, MA, 0...
Employees:29
https://www.cuebiopharma.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D26
Pipeline Score
$13M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.2x
rNPV / MCap
Top 28%
Micro Cap
(rank 653 of 905)
Percentile Rank
Cue Biopharma, Inc. faces pipeline headwinds (26/100), with $458M risk-adjusted pipeline value, led by CUE-101 in Head and Neck Squamous Cell Carcinoma (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
CUE-101
Small molecule		Head and Neck Squamous Cell CarcinomaPhase 2NCT0717225619% $395M NOT YET_RECRUITING 30 - -Feb 1, 2031 -LOW
May 24, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
CUE-101
HPV+ head and neck squamous cell carcinoma
Phase 1
2025-07-17
CUE-101
HPV+ head and neck squamous cell carcinoma
Phase 1
2025-07-17
CUE-101
HPV+ head and neck squamous cell carcinoma
Phase 1
2025-07-17
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in CUE
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CUE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CUE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CUE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
CUE Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
CUE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Cue Biopharma, Inc. (CUE) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How CUE ranks across every disease it competes in
No competitive intelligence available for CUE.